drugset / Trial / NCT04938583
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \>6 months since last platinum-based treatment.
Timeline
- Start
- 2021-03-17
- Primary completion
- 2025-10-30
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oregovomab | Monoclonal antibody | 1 mg | Intravenous |
| Subject | Oregovomab | Monoclonal antibody | 2 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |